Blog

Update (5/26/20) – Since originally publishing this post we’ve hosted a webinar on our Neoantigen Workflow. If you’d like an even deeper look at how to harness your NGS data, just click here! Leveraging neoantigens for guided treatment has become the definition of personalized cancer immunotherapy. Given their potential to …

Organizations have adopted the use of Next Generation Sequencing (NGS) as a one of the primary tools of their discovery, diagnostic and clinical efforts. Simultaneously — the number of tools available for NGS analysis has ballooned, with each tool having different capabilities for speed, accuracy, cost, etc. Seven Bridges offers …

With few exceptions, every human cell is composed of an identical DNA sequence. However, there are around 200 different cell types in our bodies. What is the underlying reason? Each different cell type represents a specific gene expression pattern. One of the main mechanisms that enables this is epigenetics. Epigenetics …

Epigenetics is an extra layer of information that is not encoded in the primary sequence of an organism’s DNA. While several mechanisms of epigenetic regulation exist, DNA methylation is one of the most commonly studied ones. Typically, the presence of methylated cytosines within a promoter region represses gene expression. The …

In the pursuit of accelerating next generation sequencing data processing for clinical applications,  Seven Bridges has developed a configurable GATK4 workflow 3.0 times faster than previous iterations. Following up on our initial push of the GATK4 workflow in 2017, and our recent update with the Broad’s Best Practices, we’ve worked …

As our understanding of biology deepens, many researchers are moving away from bulk gene expression analyses to single-cell analyses. However, current RNA-Seq methods that assay pooled RNA from tissue samples, or even from single cells, fail to conserve the spatial distribution of gene expression within the original tissue. In addition, …

Next Generation Sequencing (NGS) has brought significant improvements in all areas of biotechnology and healthcare — and cancer screening is no exception. The latest game-changer is liquid biopsy, a novel and challenging NGS application. By directly measuring and analyzing circulating tumor DNA (ctDNA) in blood, liquid biopsy is a promising, …